Indian Healthcare industry has developed significantly post TRIPS and WTO. Patent filings at the Indian patent office have been increasing at a rate of about 25% for the past 8 years. The 2005 Amendment was aimed to address issues like global competition, high innovation risks, facilitating high investments in R&D, etc which are essential for changing the trade environment in terms of production and marketing to increase drug availability to common masses.
However, development in Indian Healthcare sector is constrained by lack of patent protection, limited awareness to patent practices and its related benefits. This consequently leads to less number of patent application fillings and basically it is targeted only to generic drug manufactures.
The major Objectives of this Conference are:-
1) Evaluation of Patent Law in the context of encouraging innovation & IPR protection to pharmaceutical products.
2) Review the role of the following in encouraging investment in R&D & innovation:-
a) Data Protection & non-reliance
b) Patent Linkage
c) Section 3d
3) Effects of modernization of patent offices, practices and amended patent law on patent applications and patents in pharmaceuticals sector.
4) Examine various amendments in patent law since India signed TRIPS agreement & its role in encouraging/dis-incentivising (as the case may be) R&D for unmet medical needs of the country
Registration Fees: Rs 2,000/- Per Delegate